PR Newswire Clinical TrialsOriginal article
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
ASC36ASC36_35 FDCASC35Positive
AI Analysis
Summary
Ascletis submitted two IND applications to the FDA for obesity treatments: ASC36 once-monthly injection and ASC36_35 FDC, a potentially first-in-class co-formulation targeting amylin receptor, GLP-1R and GIPR. ASC36_35 FDC demonstrated approximately 51% greater relative body weight reduction in prior studies.
Outcome Details
Two IND applications submitted for ASC36 once-monthly injection and ASC36_35 FDC once-monthly injection
Importance:6/10
Sentiment:
0.60
IND filingObesity treatmentPeptide therapyAmylin receptor agonistGLP-1R/GIPR agonistOnce-monthly injection
Read the original article
Published by PR Newswire Clinical Trials on July 6, 2026 1:10 AM